About: Filibuvir

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Filibuvir (also known as PF-00868554, PF-868554) was a non-nucleoside orally available NS5B inhibitor developed by Pfizer for the treatment of hepatitis C. It binds to the non-catalytic Thumb II allosteric pocket of NS5B viral polymerase and causes a decrease in viral RNA synthesis. It is a potent and selective inhibitor, with a mean IC50 of 0.019 μM against genotype 1 polymerases. Several filibuvir-resistant mutations have been identified, M423 being the most common that occurred after filibuvir monotherapy. It was intended to be taken twice-daily.

Property	Value
dbo:abstract	Filibuvir (also known as PF-00868554, PF-868554) was a non-nucleoside orally available NS5B inhibitor developed by Pfizer for the treatment of hepatitis C. It binds to the non-catalytic Thumb II allosteric pocket of NS5B viral polymerase and causes a decrease in viral RNA synthesis. It is a potent and selective inhibitor, with a mean IC50 of 0.019 μM against genotype 1 polymerases. Several filibuvir-resistant mutations have been identified, M423 being the most common that occurred after filibuvir monotherapy. It was intended to be taken twice-daily. Its investigation was discontinued in February 2013 due to strategic reasons. (en)
dbo:casNumber	877130-28-4
dbo:chEMBL	490672
dbo:fdaUniiCode	198J479Y2L
dbo:kegg	D09616
dbo:pubchem	54708673
dbo:thumbnail	wiki-commons:Special:FilePath/Filibuvir.svg?width=300
dbo:wikiPageID	48738750 (xsd:integer)
dbo:wikiPageLength	4276 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1068758160 (xsd:integer)
dbo:wikiPageWikiLink	dbc:NS5B_(polymerase)_inhibitors dbr:Pfizer dbc:Abandoned_drugs dbc:Cyclopentanes dbc:Lactones dbc:Triazoles dbr:NS5B dbc:Pyridines dbc:Pyrimidines dbr:Hepatitis_C dbr:IC50
dbp:atcPrefix	none (en)
dbp:c	29 (xsd:integer)
dbp:casNumber	877130 (xsd:integer)
dbp:chembl	490672 (xsd:integer)
dbp:chemspiderid	26286922 (xsd:integer)
dbp:h	37 (xsd:integer)
dbp:iupacName	-2 (xsd:integer)
dbp:kegg	D09616 (en)
dbp:legalStatus	Development terminated (en)
dbp:n	5 (xsd:integer)
dbp:o	3 (xsd:integer)
dbp:pdbLigand	AG0 (en)
dbp:pubchem	54708673 (xsd:integer)
dbp:routesOfAdministration	Oral (en)
dbp:smiles	CCC1=CCCC[C@@]2C5CCCC5 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	SLVAPEZTBDBAPI-GDLZYMKVSA-N (en)
dbp:synonyms	PF-00868554 (en)
dbp:unii	198 (xsd:integer)
dbp:width	275 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Ebicite dbt:Fdacite dbt:RNA_antivirals dbt:Antiinfective-drug-stub
dcterms:subject	dbc:NS5B_(polymerase)_inhibitors dbc:Abandoned_drugs dbc:Cyclopentanes dbc:Lactones dbc:Triazoles dbc:Pyridines dbc:Pyrimidines
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Filibuvir (also known as PF-00868554, PF-868554) was a non-nucleoside orally available NS5B inhibitor developed by Pfizer for the treatment of hepatitis C. It binds to the non-catalytic Thumb II allosteric pocket of NS5B viral polymerase and causes a decrease in viral RNA synthesis. It is a potent and selective inhibitor, with a mean IC50 of 0.019 μM against genotype 1 polymerases. Several filibuvir-resistant mutations have been identified, M423 being the most common that occurred after filibuvir monotherapy. It was intended to be taken twice-daily. (en)
rdfs:label	Filibuvir (en)
owl:sameAs	yago-res:Filibuvir wikidata:Filibuvir dbpedia-fa:Filibuvir dbpedia-vi:Filibuvir https://global.dbpedia.org/id/2MiQz
prov:wasDerivedFrom	wikipedia-en:Filibuvir?oldid=1068758160&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Filibuvir.svg
foaf:isPrimaryTopicOf	wikipedia-en:Filibuvir
is dbo:wikiPageRedirects of	dbr:C29H37N5O3
is dbo:wikiPageWikiLink of	dbr:C29H37N5O3 dbr:NS5B_(Hepacivirus) dbr:List_of_drugs:_Fi
is foaf:primaryTopic of	wikipedia-en:Filibuvir